Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NEO-COMBAT XL: Neoadjuvant and Maintenance XL092 and Cemiplimab in BRAF V600E-wildtype Anaplastic Thyroid Cancer: a Phase 1B Study

NCT06902376 is registered in ClinicalTrials.gov with UNC Lineberger Comprehensive Cancer Center as lead sponsor.

NCT NCT06902376
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06902376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NEO-COMBAT XL: Neoadjuvant and Maintenance XL092 and Cemiplimab in BRAF V600E-wildtype Anaplastic Thyroid Cancer: a Phase 1B Study
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
June 3, 2025
Completion date
August 31, 2028
Enrollment
12 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic thyroid cancer, braf mutation-related tumors, thyroid cancer